Purine nucleotides are degraded via deamination and oxidation to uric acid, which is excreted in urine. AMP → IMP → inosine → hypoxanthine → xanthine → uric acid. Xanthine oxidase catalyzes the final two steps. Uric acid solubility limits determine serum levels; supersaturation leads to crystal formation and gout.
From your knowledge of nucleotide structure, you know that purines (adenine and guanine) have a distinctive double-ring system. When purine nucleotides are no longer needed — because DNA or RNA has been turned over, or because excess nucleotides must be cleared — cells disassemble them through a degradation pathway whose final product in humans is uric acid. Unlike pyrimidines, which are broken down into highly soluble compounds (CO₂, NH₃, and simple organic acids), the purine ring cannot be cleaved open by human enzymes. We lack the enzyme uricase that most other mammals possess, so uric acid is our metabolic dead end.
The degradation pathway follows a logical sequence of stripping and oxidizing. Starting from AMP, the first step is deamination by AMP deaminase, converting AMP to IMP (removing the amino group from the adenine ring). The phosphate is then removed by a nucleotidase to yield the nucleoside inosine, and the ribose sugar is cleaved off by purine nucleoside phosphorylase to release the free base hypoxanthine. From the guanine side, GMP is first dephosphorylated to guanosine, then the ribose is removed to yield guanine, which is deaminated to xanthine. The two paths converge at xanthine, and the enzyme xanthine oxidase catalyzes the final two oxidation steps: hypoxanthine → xanthine → uric acid.
The clinical significance of this pathway centers on one physical chemistry fact: uric acid is poorly soluble in water. At physiological pH, serum uric acid concentrations sit near the saturation limit (~6.8 mg/dL). Anything that increases purine degradation — high-purine diets, rapid cell turnover (as in tumor lysis syndrome), or genetic overproduction — can push uric acid above its solubility threshold. When this happens, monosodium urate crystals precipitate in joints and soft tissues, triggering the intense inflammatory response known as gout. The big toe's first metatarsophalangeal joint is a classic site because it is the coolest peripheral joint, and urate solubility decreases with temperature.
This pathway is also the target of important drugs. Allopurinol, a structural analog of hypoxanthine, inhibits xanthine oxidase, blocking the final two steps and reducing uric acid production. Its metabolite oxypurinol binds tightly to the enzyme, providing sustained inhibition. Febuxostat is a newer, non-purine xanthine oxidase inhibitor. Understanding the degradation pathway makes the drug logic transparent: if you cannot open the purine ring or add uricase (though recombinant uricase, rasburicase, exists for acute use), the next best strategy is to block the last oxidation steps so that the more soluble precursors hypoxanthine and xanthine accumulate instead of insoluble uric acid.